1,2-Distearoyl-sn-glycero-3-PC Mechanisms, Clinical Value, a

1,2-Distearoyl-sn-glycero-3-PC: Mechanisms, Clinical Value, and Research Applications in Drug Delivery Systems

Introduction
1,2-Distearoyl-sn-glycero-3-phosphocholine (1,2-DSGPC or DSPC) is a synthetic phospholipid widely used in the formulation of liposomes and lipid nanoparticles for pharmaceutical and biomedical applications. Structurally, DSPC consists of a glycerol backbone esterified with two stearic acid (C18:0) chains at the sn-1 and sn-2 positions, and a phosphocholine head group at the sn-3 position. This configuration imparts DSPC with a high phase transition temperature (Tm ≈ 55°C), conferring stability and rigidity to lipid bilayers formed from this molecule (Torchilin, 2005, Nat Rev Drug Discov).

The mechanism of action of DSPC is not pharmacological per se, but rather physicochemical. It serves as a key structural component in liposomal and lipid nanoparticle systems, providing membrane integrity, modulating drug release kinetics, and enhancing the in vivo stability of encapsulated therapeutics. By forming stable bilayers, DSPC enables the encapsulation and controlled delivery of a wide range of drugs, including chemotherapeutics, nucleic acids, and vaccines (Allen & Cullis, 2013, Adv Drug Deliv Rev).

[Related: N1-Propyl-Pseudo-UTP] Clinical Value and Applications
DSPC has become a cornerstone in the development of advanced drug delivery systems, particularly in the formulation of liposomes and lipid nanoparticles (LNPs). Its high phase transition temperature and saturated acyl chains make it ideal for creating robust, long-circulating vesicles that resist premature leakage and degradation in the bloodstream.

One of the most significant clinical applications of DSPC is in the formulation of liposomal doxorubicin (Doxil®/Caelyx®), a chemotherapeutic agent used in the treatment of various cancers. The inclusion of DSPC in the liposomal bilayer enhances the stability of the formulation, reduces cardiotoxicity, and prolongs circulation time, resulting in improved therapeutic outcomes (Barenholz, 2012, J Control Release).

[Related: Concanavalin] More recently, DSPC has played a pivotal role in the development of mRNA-based vaccines, such as those used against SARS-CoV-2. In these formulations, DSPC is a key component of the lipid nanoparticle shell that protects the mRNA payload, facilitates cellular uptake, and ensures efficient endosomal escape (Hou et al., 2021, Nat Rev Mater). The clinical success of these vaccines has underscored the importance of DSPC in modern pharmaceutical technology.

Beyond oncology and vaccines, DSPC-based liposomes are being explored for the delivery of antibiotics, antifungals, and gene therapies, demonstrating versatility across a wide spectrum of therapeutic areas (Bulbake et al., 2017, Pharmaceutics).

[Related: Calcium Phosphate Cell] Key Challenges and Pain Points Addressed
Traditional drug delivery methods often suffer from poor bioavailability, rapid clearance, off-target toxicity, and instability of the therapeutic agent. DSPC addresses several of these challenges:

1. **Stability and Shelf-life**: The saturated nature of DSPC's fatty acid chains and its high phase transition temperature confer exceptional stability to liposomal membranes, reducing the risk of drug leakage and degradation during storage and circulation (Allen & Cullis, 2013).

2. **Controlled Release**: DSPC-based bilayers are less permeable at physiological temperatures, enabling sustained and controlled release of encapsulated drugs, which is critical for maintaining therapeutic concentrations over time (Barenholz, 2012).

3. **Reduced Immunogenicity and Toxicity**: By encapsulating drugs within DSPC liposomes, exposure to non-target tissues is minimized, reducing systemic toxicity and adverse immune reactions (Torchilin, 2005).

4. **Enhanced Circulation Time**: DSPC's physicochemical properties, especially when combined with polyethylene glycol (PEG)-modified lipids, result in "stealth" liposomes that evade the mononuclear phagocyte system, prolonging systemic circulation (Allen & Cullis, 2013).

5. **Versatility**: DSPC can be used to encapsulate both hydrophilic and hydrophobic drugs, nucleic acids, and proteins, making it a flexible platform for diverse therapeutic modalities (Bulbake et al., 2017).

Literature Review
A substantial body of research supports the utility and efficacy of DSPC in pharmaceutical formulations:

1. **Barenholz, Y. (2012). "Doxil®—The first FDA-approved nano-drug: Lessons learned." J Control Release, 160(2), 117-134.**
This review highlights the critical role of DSPC in the formulation of Doxil®, emphasizing its contribution to liposome stability, reduced toxicity, and enhanced efficacy in cancer therapy.

2. **Allen, T.M., & Cullis, P.R. (2013). "Liposomal drug delivery systems: From concept to clinical applications." Adv Drug Deliv Rev, 65(1), 36-48.**
The authors discuss the physicochemical properties of DSPC and its impact on the pharmacokinetics and biodistribution of liposomal drugs, with a focus on clinical translation.

3. **Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021). "Lipid nanoparticles for mRNA delivery." Nat Rev Mater, 6, 1078–1094.**
This paper reviews the design and optimization of lipid nanoparticles for mRNA vaccines, highlighting the essential role of DSPC in achieving efficient delivery and immunogenicity.

4. **Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017). "Liposomal formulations in clinical use: An updated review." Pharmaceutics, 9(2), 12.**
The review provides an overview of clinically approved liposomal formulations, many of which utilize DSPC for its stability and biocompatibility.

5. **Torchilin, V.P. (2005). "Recent advances with liposomes as pharmaceutical carriers." Nat Rev Drug Discov, 4(2), 145-160.**
Torchilin discusses the advancements in liposome technology, with specific reference to the role of DSPC in enhancing the performance of drug delivery systems.

6. **Kulkarni, J.A., Witzigmann, D., Thomson, S.B., et al. (2019). "The current landscape of nucleic acid therapeutics." Nat Nanotechnol, 14, 946–954.**
The paper examines the use of DSPC in lipid nanoparticle formulations for nucleic acid delivery, including siRNA and mRNA, underscoring its importance in the field.

7. **Immordino, M.L., Dosio, F., & Cattel, L. (2006). "Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential." Int J Nanomedicine, 1(3), 297-315.**
This review elaborates on the use of DSPC in stealth liposome formulations, discussing its impact on pharmacokinetics and immune evasion.

Experimental Data and Results
Experimental studies have consistently demonstrated the advantages of DSPC-containing liposomes and lipid nanoparticles:

- **Stability and Drug Retention**: In a comparative study, DSPC-based liposomes exhibited significantly lower leakage rates of encapsulated doxorubicin at 37°C compared to liposomes formulated with unsaturated phospholipids (Barenholz, 2012). This stability is attributed to the tight packing of saturated acyl chains and the high Tm of DSPC.

- **Pharmacokinetics and Biodistribution**: Preclinical models have shown that DSPC/Cholesterol/PEG-lipid formulations result in prolonged circulation half-lives and reduced uptake by the liver and spleen, enhancing drug accumulation at tumor sites (Allen & Cullis, 2013).

- **Efficacy in mRNA Vaccines**: The inclusion of DSPC in LNPs for mRNA vaccines has been shown to increase the efficiency of mRNA delivery and protein expression in vivo, as evidenced by robust immune responses in both preclinical and clinical studies (Hou et al., 2021).

- **Reduced Toxicity**: Clinical data from Doxil® trials indicate that DSPC-based liposomes significantly reduce the incidence of cardiotoxicity and other adverse effects compared to free doxorubicin (Barenholz, 2012).

- **Versatility**: DSPC liposomes have been successfully used to encapsulate a variety of drugs, including amphotericin B, cytarabine, and irinotecan, demonstrating broad applicability (Bulbake et al., 2017).

Usage Guidelines and Best Practices
The successful application of DSPC in pharmaceutical formulations requires attention to several key factors:

1. **Lipid Composition**: DSPC is typically combined with cholesterol (to modulate membrane fluidity), PEGylated lipids (for stealth properties), and other functional lipids depending on the intended application. The molar ratios must be optimized for each drug and delivery route (Allen & Cullis, 2013).

2. **Hydration and Extrusion**: DSPC requires hydration above its phase transition temperature (typically 60–65°C) to ensure proper bilayer formation. Subsequent extrusion through polycarbonate membranes is used to control vesicle size and uniformity.

3. **Encapsulation Methods**: Hydrophilic drugs are typically loaded using passive encapsulation during liposome formation, while remote loading techniques (e.g., ammonium sulfate gradient) are used for weakly basic drugs such as doxorubicin (Barenholz, 2012).

4. **Sterilization and Storage**: DSPC liposomes should be sterilized by filtration and stored at 2–8°C. The high Tm of DSPC minimizes drug leakage during storage, but formulations should be monitored for physical stability and drug retention.

5. **Quality Control**: Analytical methods such as dynamic light scattering (DLS), transmission electron microscopy (TEM), and high-performance liquid chromatography (HPLC) are employed to assess size distribution, morphology, and drug content.

6. **Regulatory Considerations**: DSPC is generally regarded as safe (GRAS) for parenteral use, but final formulations must comply with regulatory guidelines for excipients, sterility, and endotoxin levels.

Future Research Directions
While DSPC has established itself as a fundamental component of advanced drug delivery systems, ongoing research aims to further enhance its utility:

- **Targeted Delivery**: The incorporation of targeting ligands (e.g., antibodies, peptides) onto DSPC-based liposomes is being explored to improve site-specific drug delivery and reduce off-target effects (Immordino et al., 2006).

- **Stimuli-Responsive Systems**: Research is underway to develop DSPC-based liposomes that respond to external stimuli (e.g., pH, temperature, ultrasound) for controlled drug release at the disease site.

- **Combination Therapies**: DSPC liposomes are being evaluated for the co-delivery of multiple therapeutic agents (e.g., chemotherapy and immunotherapy) to achieve synergistic effects.

- **Gene and RNA Delivery**: With the success of mRNA vaccines, further optimization of DSPC-containing LNPs for the delivery of siRNA, miRNA, and CRISPR components is a major focus (Kulkarni et al., 2019).

- **Biodegradability and Immunogenicity**: Efforts are ongoing to fine-tune the biodegradability and immunogenicity of DSPC-based systems, particularly for repeated dosing and chronic therapies.

- **Scale-Up and Manufacturing**: Advances in microfluidic technologies and continuous manufacturing are being investigated to enable large-scale, reproducible production of DSPC-based formulations.

Conclusion
1,2-Distearoyl-sn-glycero-3-PC (DSPC) is a critical excipient in the formulation of liposomal and lipid nanoparticle drug delivery systems. Its unique physicochemical properties confer stability, controlled release, and biocompatibility, addressing key challenges in modern therapeutics. Supported by extensive clinical and experimental evidence, DSPC continues to enable innovations in oncology, vaccines, and gene therapy. Future research will further expand its applications, with a focus on targeted, responsive, and combination therapies.

Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 16203 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11362511